HSIC · Henry Schein Inc · Financials

$85.25 -3.00 (-3.39%) Play latest call Q3 2026 earnings call transcript

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$9.75B

110.54M

Volume · Nov 5 714.86K Avg daily vol (3M) 1.23M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$13.18B +4%

FY2025

Net Income

$398M +2.1%

FY2025

Gross Margin

31.14% -0.6pp

FY2025

Operating Margin

4.95% 0pp

FY2025

Diluted EPS

$3.27 +7.2%

FY2025

Operating Cash Flow

$712M -16%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+1.4%	+5.4%	+2.2%	—	$13.73B	$13.18B	$12.67B	$12.34B	$12.65B	$12.4B	$10.12B	$9.99B	$13.2B	$12.46B	$11.57B	$10.63B	$10.37B	$9.56B	$8.94B	$8.53B	—	—	—
Cost of Revenue	+1.0%	+4.4%	+1.8%	—	$9.4B	$9.08B	$8.66B	$8.48B	$8.82B	$8.73B	$7.3B	$6.89B	$6.51B	$6.14B	$8.35B	$7.62B	$7.46B	$6.9B	$6.43B	$6.11B	$5.36B	$4.62B	$4.51B
Gross Profit	+2.3%	+7.8%	+3.2%	—	$4.34B	$4.11B	$4.02B	$3.86B	$3.83B	$3.67B	$2.82B	$3.09B	$2.91B	$2.75B	$3.23B	$3.01B	$2.91B	$2.66B	$2.51B	$2.42B	$2.17B	$1.92B	$1.87B
Gross Margin	—	—	—	—	—	31.14%	31.69%	31.28%	30.29%	29.63%	27.83%	30.95%	22.05%	22.04%	27.88%	28.29%	28.07%	27.78%	28.05%	28.35%	—	—	—
Selling, General & Administrative	+3.6%	+8.1%	+3.3%	—	$3.27B	$3.08B	$3.03B	$2.96B	$2.77B	$2.63B	$2.09B	$2.36B	$2.22B	$2.07B	$2.41B	$2.24B	$2.2B	$1.98B	$1.87B	$1.84B	$1.64B	$1.45B	$1.43B
Amortization of Intangibles	+12.6%	+11.2%	+6.8%	—	—	$180M	$185M	$152M	$126M	$124M	$106M	$108.3M	$75.3M	$70.3M	$98.2M	$92.9M	$89.6M	$69.2M	$68.5M	$58.8M	$48.4M	—	—
Depreciation & Amortization	+13.6%	+10.8%	+6.9%	—	$333M	$311M	$297M	$248M	$212M	$210M	$186M	$184.94M	$143.63M	$133.86M	$169.78M	$159.13M	$152.24M	$128.04M	$125.32M	$115.9M	$101.21M	$81.49M	$78.13M
Restructuring Charges	-6.4%	—	+11.6%	—	$86M	$105M	$110M	$80M	$128M	$8M	—	—	$54.37M	$0	$45.89M	$34.93M	$0	$0	$15.19M	$0	$12.29M	$3.02M	$23.24M
Total Operating Expenses	—	—	—	—	—	—	—	—	—	—	—	—	$2.7B	$2.53B	$2.41B	—	—	—	—	—	—	—	—
Operating Income	-4.4%	+4.1%	-1.2%	—	$709M	$653M	$621M	$615M	$747M	$852M	$535M	$718.26M	$600.62M	$669.76M	$771.57M	$733.97M	$715.14M	$677.05M	$618.96M	$582.15M	$521.13M	$464.09M	$419.29M
Operating Margin	—	—	—	—	—	4.95%	4.9%	4.98%	5.91%	6.87%	5.29%	7.19%	4.55%	5.37%	6.67%	6.9%	6.9%	7.08%	6.92%	6.82%	—	—	—
EBITDA	+0.2%	+6.0%	+0.8%	—	$1.04B	$964M	$918M	$863M	$959M	$1.06B	$721M	$903.2M	$744.25M	$803.62M	$941.35M	$893.1M	$867.38M	$805.09M	$744.28M	$698.05M	$622.35M	$545.58M	$497.41M
Interest Expense	+62.4%	+29.6%	+19.2%	—	$163M	$150M	$131M	$87M	$35M	$27M	$41M	$50.79M	$76.02M	$51.07M	$31.89M	$26.01M	$24.06M	$27.54M	$30.9M	$30.38M	$33.64M	$23.37M	$34.61M
Interest Income	+60.4%	+27.0%	+9.8%	—	$33M	$33M	$24M	$17M	$8M	$6M	$10M	$15.76M	$15.49M	$12.44M	$13.28M	$12.94M	$13.66M	$12.85M	$13.39M	$15.59M	$14.1M	$9.98M	$16.36M
Other Non-Operating Income	—	—	—	—	$1M	-$3M	-$1M	-$3M	$1M	$0	-$4M	-$2.92M	-$3.26M	-$1.34M	$2.88M	-$141K	$4.57M	$2.33M	$2.74M	$1.94M	$447K	$2.03M	-$5.59M
Equity in Earnings of Unconsolidated Entities	-7.2%	0.0%	-1.6%	—	$4M	$12M	$13M	$14M	$15M	$20M	$12M	$17.9M	$21.04M	$15.29M	$18.52M	$14.06M	$11.73M	$10.19M	$7.06M	$15.56M	$10.17M	$5.24M	$5.04M
Pretax Income	-9.6%	+1.3%	-3.0%	—	$580M	$533M	$513M	$542M	$721M	$831M	$500M	$680.31M	$536.84M	$629.79M	$755.84M	$720.76M	$709.31M	$664.69M	$604.19M	$569.31M	$502.04M	$452.72M	$395.45M
Income Tax	-9.5%	+5.8%	-5.0%	—	$141M	$126M	$128M	$120M	$170M	$198M	$95M	$159.52M	$107.43M	$308.98M	$217.96M	$211.39M	$215.61M	$190.89M	$187.86M	$180.21M	$160.07M	$127.52M	$131.21M
Net Income	-9.6%	-0.3%	-1.8%	—	$421M	$398M	$390M	$416M	$538M	$631M	$404M	$694.73M	$535.88M	$406.3M	$506.78M	$479.06M	$466.08M	$431.55M	$388.08M	$367.66M	$325.79M	$311.15M	$239.46M
Net Margin	—	—	—	—	—	3.02%	3.08%	3.37%	4.25%	5.09%	3.99%	6.96%	4.06%	3.26%	4.38%	4.51%	4.49%	4.51%	4.34%	4.31%	—	—	—
Net Income Attributable to Noncontrolling Interests	-9.1%	+5.6%	-7.2%	—	$22M	$21M	$8M	$20M	$28M	$29M	$16M	$24.4M	$26.25M	$52.99M	$49.62M	$44.37M	$39.36M	$39.91M	$35.31M	$37M	$26.34M	$22M	$21.92M
Comprehensive Income	+5.0%	+3.5%	+4.5%	—	$456M	$551M	$217M	$443M	$476M	$568M	$463M	$682.72M	$417.18M	$593.27M	$409.68M	$354.25M	$303.1M	$446.55M	$418.35M	$359.73M	$292.11M	$345.63M	$168.91M
EPS (Basic) USD/shares	-5.9%	+3.1%	+1.3%	—	$3.68	$3.29	$3.07	$3.18	$3.95	$4.51	$2.83	$4.70	$3.51	$2.59	$3.14	$2.89	$5.53	$5.02	$4.44	$4.08	$3.62	$3.50	$2.69
EPS (Diluted) USD/shares	-5.8%	+3.0%	+1.4%	$5.29 – $5.39*	$3.65	$3.27^G	$3.05^G	$3.16^G	$3.91^G	$4.45^G	$2.82	$4.65	$3.49	$2.57	$3.10	$2.85	$5.44	$4.93	$4.32	$3.97	$3.49	$3.44	$2.63
Shares Outstanding (Basic Avg) shares	-3.9%	-3.2%	-3.1%	—	—	120.81M	126.79M	130.62M	136.06M	140.09M	142.5M	147.82M	152.66M	156.79M	161.64M	165.69M	84.27M	85.93M	87.5M	90.12M	90.1M	88.87M	89.08M
Shares Outstanding (Diluted Avg) shares	-4.0%	-3.2%	-3.2%	—	—	121.72M	127.78M	131.75M	137.76M	141.77M	143.4M	149.26M	153.71M	158.21M	163.72M	168.25M	85.74M	87.62M	89.82M	92.62M	93.27M	90.56M	91.22M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $5.71B in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Current long-term debt and lease obligations	2026-09-26	USD 142,000,000	10-Q filed 2026-11-03
Current operating lease liabilities	2026-09-26	USD 79,000,000	10-Q filed 2026-11-03
Finance lease liabilities	2026-09-26	USD 6,000,000	10-Q filed 2026-11-03
Noncurrent long-term debt and lease obligations	2026-09-26	USD 2,382,000,000	10-Q filed 2026-11-03
Noncurrent operating lease liabilities	2026-09-26	USD 288,000,000	10-Q filed 2026-11-03
Short-term borrowings	2026-09-26	USD 1,000,000,000	10-Q filed 2026-11-03

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

0.88×

Medical Distribution median 0.56×

EV/EBIT

17.06×

Medical Distribution median 24.60×

P/E (TTM)

24.18×

Price/Sales (TTM)

0.71×

Medical Distribution median 0.27×

Price/Book

3.09×

Medical Distribution median 6.30×

EV/Adj. EBITDA (FY2025)

10.98×

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA (non-GAAP)”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA (non-GAAP)”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Global Distribution and Value Added Services	$11,138,000,000	$10,760,000,000	$10,561,000,000	$10,975,000,000	—	—	—	—
Global Specialty Products	$1,544,000,000	$1,446,000,000	$1,331,000,000	$1,273,000,000	—	—	—	—
Global Technology	$675,000,000	$630,000,000	$602,000,000	$549,000,000	—	—	—	—
Corporate TSA	—	—	—	$0	—	$75,000,000	$81,267,000	$0
Healthcare Distribution	—	—	$11,533,000,000	$11,924,000,000	$11,754,000,000	$9,530,000,000	$9,389,451,000	$9,009,164,000
Technology	—	—	$806,000,000	$723,000,000	$647,000,000	$514,000,000	$515,085,000	$408,439,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$9,096,000,000	$8,825,000,000	$8,662,000,000	$9,197,000,000	$8,722,000,000	$7,090,000,000	$6,876,194,000	$6,411,558,000
Non Us	$4,088,000,000	$3,848,000,000	$3,677,000,000	—	—	—	—	—
Locations Other Than United States	—	—	—	$3,450,000,000	$3,679,000,000	$3,029,000,000	$3,109,609,000	$3,006,045,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Global Distribution and Value Added Services	$680,000,000	$696,000,000	$665,000,000	$833,000,000	—	—	—	—
Global Specialty Products	$242,000,000	$178,000,000	$175,000,000	$192,000,000	—	—	—	—
Global Technology	$180,000,000	$152,000,000	$142,000,000	$125,000,000	—	—	—	—
Healthcare Distribution	—	—	$470,000,000	$619,000,000	$727,000,000	$436,000,000	$591,404,000	$490,988,000
Technology	—	—	$145,000,000	$128,000,000	$125,000,000	$99,000,000	$126,857,000	$109,631,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Global Distribution and Value Added Services	6.1%	6.5%	6.3%	7.6%	—	—	—	—
Global Specialty Products	15.7%	12.3%	13.1%	15.1%	—	—	—	—
Global Technology	26.7%	24.1%	23.6%	22.8%	—	—	—	—
Healthcare Distribution	—	—	4.1%	5.2%	6.2%	4.6%	6.3%	5.4%
Technology	—	—	18%	17.7%	19.3%	19.3%	24.6%	26.8%

Key facts CIK 1000228 CUSIP 806407102 13F (30d) 251 filings 235 filers Visit website Investor relations